FDA accepts NDA amendment and new PDUFA date of February 26, 2023 for pegcetacoplan for geographic atrophy.- Apellis
Apellis Pharmaceuticals, Inc. announced that the FDA has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
The updated Prescription Drug User Fee Act (PDUFA) goal date is February 26, 2023.
The FDA also restated that they do not plan to hold an advisory committee meeting to discuss the application.
Apellis announced earlier this month the company’s decision to submit 24-month efficacy data from the Phase III DERBY and OAKS studies as part of the NDA review. The 24-month data showed increasing and consistent effects with every-other-month and monthly pegcetacoplan treatment and a favorable safety profile in both studies. Apellis remains on track to submit an EU marketing authorization application, which will also include the 24-month results, to the European Medicines Agency by the end of 2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.